289 related articles for article (PubMed ID: 23728706)
1. Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy.
Peng PJ; Ou XQ; Chen ZB; Liao H; Peng YL; Wang SY; Zhang HY; Lin Z
Cancer Chemother Pharmacol; 2013 Aug; 72(2):323-8. PubMed ID: 23728706
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma.
Li YH; Wang FH; Jiang WQ; Xiang XJ; Deng YM; Hu GQ; Xu DM; Chen Y; Lin Q; He YJ
Cancer Chemother Pharmacol; 2008 Aug; 62(3):539-44. PubMed ID: 18172651
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
Lee J; Im YH; Cho EY; Hong YS; Lee HR; Kim HS; Kim MJ; Kim K; Kang WK; Park K; Shim YM
Cancer Chemother Pharmacol; 2008 Jun; 62(1):77-84. PubMed ID: 17762932
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer.
Chua DT; Yiu HH; Seetalarom K; Ng AW; Kurnianda J; Shotelersuk K; Krishnan G; Hong RL; Yang MH; Wang CH; Sze WK; Ng WT
Head Neck; 2012 Sep; 34(9):1225-30. PubMed ID: 22076785
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer.
Chua D; Wei WI; Sham JS; Au GK
Jpn J Clin Oncol; 2008 Apr; 38(4):244-9. PubMed ID: 18407933
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of capecitabine plus cisplatin in patients with gastric cancer.
Salah-Eldin MA; Ebrahim MA; AL-Ashry MS
Anticancer Drugs; 2009 Mar; 20(3):191-6. PubMed ID: 19396018
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens.
Baize N; Abakar-Mahamat A; Mounier N; Berthier F; Caroli-Bosc FX
Cancer Chemother Pharmacol; 2009 Aug; 64(3):549-55. PubMed ID: 19123051
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
13. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
Yoshimoto M; Takao S; Hirata M; Okamoto Y; Yamashita S; Kawaguchi Y; Takami M; Furusawa H; Morita S; Abe C; Sakamoto J
Cancer Chemother Pharmacol; 2012 Aug; 70(2):331-8. PubMed ID: 22526409
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
[TBL] [Abstract][Full Text] [Related]
15. A pilot phase II study of capecitabine plus cisplatin in the treatment of recurrent carcinoma of the uterine cervix.
Benjapibal M; Thirapakawong C; Leelaphatanadit C; Therasakvichya S; Inthasorn P
Oncology; 2007; 72(1-2):33-8. PubMed ID: 17998788
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.
Park YH; Lee JL; Ryoo BY; Ryu MH; Yang SH; Kim BS; Shin DB; Chang HM; Kim TW; Yuh YJ; Kang YK
Cancer Chemother Pharmacol; 2008 Apr; 61(4):623-9. PubMed ID: 17522863
[TBL] [Abstract][Full Text] [Related]
17. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.
Chan AT; Hsu MM; Goh BC; Hui EP; Liu TW; Millward MJ; Hong RL; Whang-Peng J; Ma BB; To KF; Mueser M; Amellal N; Lin X; Chang AY
J Clin Oncol; 2005 May; 23(15):3568-76. PubMed ID: 15809453
[TBL] [Abstract][Full Text] [Related]
18. Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer.
Liu C; Sun Q; Hang X; Zhong B; Wang D
Anticancer Drugs; 2008 Sep; 19(8):825-31. PubMed ID: 18690095
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer.
Lee SS; Kim SB; Park SI; Kim YH; Ryu JS; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
Jpn J Clin Oncol; 2007 Nov; 37(11):829-35. PubMed ID: 17951334
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma.
Peng PJ; Lv BJ; Tang C; Liao H; Lin Z; Liu YM; Wang ZH; Wang SY; Cheng ZB
Drug Des Devel Ther; 2015; 9():6401-5. PubMed ID: 26677316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
